Additionally, the chemogenetic inhibition of this population, or the targeted overexpression of mitochondrial UCP2 in such population, or systemic application of a mitochondrial-targeting antioxidant drug Mito-Q could effectively ameliorate HE. This evidence concerns the gene UCP2 and hereditary elliptocytosis.